{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:30:50Z","timestamp":1786609850521,"version":"build-2736575974"},"reference-count":117,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Immunotherapy delivers a fundamental shift in the treatment of multiple cancers, offering hope for patients with cancer. Unlike conventional therapies, it leverages the patient\u2019s immune system to precisely identify and destroy cancer cells. The remarkable journey of immunotherapy\u2019s has revolutionized oncology and paved the way for the development of modern immunotherapies. Several approaches are applied for immunotherapy, including immune checkpoint inhibitors, adoptive cell therapies, cancer vaccines, tumor microenvironment reprogramming, monoclonal antibodies, cytokine therapies, oncolytic virus therapy and combination strategies. Various immunotherapies are being used for different types of cancers like skin, lung, bladder, kidney, liver, breast and blood cancers. Despite providing an effective cancer treatment, immunotherapies face some challenges in their clinical implementation. To overcome these limitations, future directions emphasize the development of personalized and combination therapies, the incorporation of AI and a good delivery system. The main aim of this review is to give an overview of the journey of evolution, different approaches, limitations, advances and future development for immunotherapy in cancer treatment.<\/jats:p>","DOI":"10.3390\/ijms27167216","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:06:16Z","timestamp":1786608376000},"page":"7216","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy for Cancer: Current Advances and Future Directions"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2172-4235","authenticated-orcid":false,"given":"Tanya","family":"Saxena","sequence":"first","affiliation":[{"name":"National Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamsuz","family":"Zaman","sequence":"additional","affiliation":[{"name":"National Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6916-014X","authenticated-orcid":false,"given":"Himanshu","family":"Dhanda","sequence":"additional","affiliation":[{"name":"National Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2782-6959","authenticated-orcid":false,"given":"Sandeep Kumar","family":"Swain","sequence":"additional","affiliation":[{"name":"National Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetu","family":"Kushwaha","sequence":"additional","affiliation":[{"name":"National Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manpreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"National Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Kamal","sequence":"additional","affiliation":[{"name":"National Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8044-4327","authenticated-orcid":false,"given":"Sufian","family":"Zaheer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-976X","authenticated-orcid":false,"given":"Pranay","family":"Tanwar","sequence":"additional","affiliation":[{"name":"Laboratory Oncology Unit, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, AIIMS, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Kumar","sequence":"additional","affiliation":[{"name":"National Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-7936","authenticated-orcid":false,"given":"Fouzia","family":"Siraj","sequence":"additional","affiliation":[{"name":"Centre for Cancer Pathology, Indian Council of Medical Research, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5367-6050","authenticated-orcid":false,"given":"Bhavika","family":"Rishi","sequence":"additional","affiliation":[{"name":"National Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2884-3600","authenticated-orcid":false,"given":"Aroonima","family":"Misra","sequence":"additional","affiliation":[{"name":"National Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"viii6","DOI":"10.1093\/annonc\/mds256","article-title":"Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer","volume":"23","author":"Finn","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_3","first-page":"124","article-title":"A history of cancer and its treatment: Presidential Address to the Ulster Medical Society. 7th October 2021","volume":"91","author":"McAleer","year":"2022","journal-title":"Ulst. Med. J."},{"key":"ref_4","first-page":"239","article-title":"Radiation therapy for cancer","volume":"3","author":"Jaffray","year":"2016","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"Chu","year":"2008","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Dobosz, P., and Dzieci\u0105tkowski, T. (2019). The intriguing history of cancer immunotherapy. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02965"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.20517\/2394-4722.2017.41","article-title":"Cancer immunotherapy: A brief review of the history, possibilities, and challenges ahead","volume":"3","author":"Oiseth","year":"2017","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_10","first-page":"4694","article-title":"Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell\u2013mediated antibody-dependent cellular cytotoxicity","volume":"121","author":"Rudnicka","year":"2013","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.14216\/kjco.24009","article-title":"The evolution of cancer immunotherapy: A comprehensive review of its history and current perspectives","volume":"20","author":"Ahuja","year":"2024","journal-title":"Korean J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Vaddepally, R.K., Kharel, P., Pandey, R., Garje, R., and Chandra, A.B. (2020). Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers, 12.","DOI":"10.3390\/cancers12030738"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Jogalekar, M.P., Rajendran, R.L., Khan, F., Dmello, C., Gangadaran, P., and Ahn, B.-C. (2022). CAR T-Cell-Based gene therapy for cancers: New perspectives, challenges, and clinical developments. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.925985"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/aob-21-3","article-title":"A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy","volume":"7","author":"Peng","year":"2022","journal-title":"Ann. Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Oyewole-Said, D., Konduri, V., Vazquez-Perez, J., Weldon, S.A., Levitt, J.M., and Decker, W.K. (2020). Beyond T-cells: Functional characterization of CTLA-4 expression in immune and non-immune cell types. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.608024"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints\u2014PD-1, PD-L1, CTLA-4\u2014New opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41419-023-06391-x","article-title":"Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy","volume":"15","author":"Babamohamadi","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"ref_20","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.2147\/DDDT.S267433","article-title":"Research status and outlook of PD-1\/PD-L1 inhibitors for cancer therapy","volume":"14","author":"Ai","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kroemer, G., and Zitvogel, L. (2021). Immune Checkpoint Inhibitors, Rockefeller University Press.","DOI":"10.1084\/jem.20201979"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"200773","DOI":"10.1016\/j.omton.2024.200773","article-title":"Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party","volume":"32","author":"Lu","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: Breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"107241","DOI":"10.1016\/j.jbc.2024.107241","article-title":"The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy","volume":"300","author":"Mariuzza","year":"2024","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wei, Y., and Li, Z. (2022). LAG3-PD-1 combo overcome the disadvantage of drug resistance. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.831407"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","article-title":"TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors","volume":"72","author":"Sauer","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.36401\/JIPO-23-4","article-title":"T cell Immunoglobulin and Mucin Domain Containing Protein 3 (TIM-3) Inhibitors in Oncology Clinical Trials: A Review","volume":"7","author":"Duong","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_29","first-page":"CD015888","article-title":"Anti-TIGIT inhibitors plus PD-1 or PD-L1 inhibitors versus PD-1 or PD-L1 inhibitors for first-line treatment of advanced non-small cell lung cancer","volume":"2025","author":"Liu","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Alnefaie, A., Albogami, S., Asiri, Y., Ahmad, T., Alotaibi, S.S., Al-Sanea, M.M., and Althobaiti, H. (2022). Chimeric antigen receptor T-cells: An overview of concepts, applications, limitations, and proposed solutions. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.797440"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"20210058","DOI":"10.1002\/EXP.20210058","article-title":"Adoptive cell therapy for cancer treatment","volume":"Volume 3","author":"Du","year":"2023","journal-title":"Proceedings of the Exploration"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2378543","DOI":"10.1080\/21645515.2024.2378543","article-title":"Approved CAR-T therapies have reproducible efficacy and safety in clinical practice","volume":"20","author":"Waghela","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1016\/j.jtct.2024.11.014","article-title":"Tumor-Infiltrating Lymphocyte Therapy: A New Frontier","volume":"31","author":"Tseng","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_34","unstructured":"Phillips, C. (2024). First Cancer TIL Therapy Gets FDA Approval for Advanced Melanomai, National Cancer Institute. Available online: https:\/\/link.springer.com\/article\/10.1186\/s42047-026-00238-3#author-information."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40164-024-00504-8","article-title":"Novel insights into TCR-T cell therapy in solid neoplasms: Optimizing adoptive immunotherapy","volume":"13","author":"Shao","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Shafer, P., Kelly, L.M., and Hoyos, V. (2022). Cancer therapy with TCR-engineered T cells: Current strategies, challenges, and prospects. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.835762"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7150\/thno.104594","article-title":"Targeting cancer with precision: Strategical insights into TCR-engineered T cell therapies","volume":"15","author":"Lin","year":"2025","journal-title":"Theranostics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Du, N., Guo, F., Wang, Y., and Cui, J. (2021). NK cell therapy: A rising star in cancer treatment. Cancers, 13.","DOI":"10.3390\/cancers13164129"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.4103\/jfmpc.jfmpc_758_23","article-title":"Vaccines for cancer prevention and cure","volume":"12","author":"Petkar","year":"2023","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e146956","DOI":"10.1172\/JCI146956","article-title":"Vaccines for immunoprevention of cancer","volume":"131","author":"Enokida","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1097\/MJT.0b013e3182068cdb","article-title":"Therapeutic cancer vaccines: The latest advancement in targeted therapy","volume":"19","author":"Bilusic","year":"2012","journal-title":"Am. J. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-025-01670-w","article-title":"Cancer vaccines: Current status and future directions","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e70434","DOI":"10.1002\/mco2.70434","article-title":"mRNA Vaccines: Current Applications and Future Directions","volume":"6","author":"Li","year":"2025","journal-title":"MedComm"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10238-024-01436-7","article-title":"Personalized neoantigen cancer vaccines: Current progression, challenges and a bright future","volume":"24","author":"Wu","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1541326","DOI":"10.3389\/or.2025.1541326","article-title":"Advancements and challenges in personalized neoantigen-based cancer vaccines","volume":"19","author":"Singh","year":"2025","journal-title":"Oncol. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Delgado, M., and Garcia-Sanz, J.A. (2023). Therapeutic monoclonal antibodies against cancer: Present and future. Cells, 12.","DOI":"10.3390\/cells12242837"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000403175","article-title":"Cancer immunology\u2014An overview","volume":"25","author":"Richards","year":"1980","journal-title":"Prog. Exp. Tumor Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of therapeutic antitumor monoclonal antibodies","volume":"81","author":"Tsao","year":"2021","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Hafeez, U., Parakh, S., Gan, H.K., and Scott, A.M. (2020). Antibody\u2013drug conjugates for cancer therapy. Molecules, 25.","DOI":"10.3390\/molecules25204764"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Buyukgolcigezli, I., Tenekeci, A.K., and Sahin, I.H. (2025). Opportunities and Challenges in Antibody\u2013Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment. Cancers, 17.","DOI":"10.20944\/preprints202502.1917.v1"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"22357","DOI":"10.1038\/s41598-024-68311-z","article-title":"Antibody\u2013drug conjugates and immune checkpoint inhibitors in cancer treatment: A systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1565859","DOI":"10.1080\/2162402X.2019.1565859","article-title":"Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells","volume":"8","author":"Bauzon","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2394229","DOI":"10.1080\/19420862.2024.2394229","article-title":"Developability considerations for bispecific and multispecific antibodies","volume":"Volume 16","author":"Amash","year":"2024","journal-title":"Proceedings of the MAbs"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: Mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1007\/s13346-021-01036-y","article-title":"Overcoming physical stromal barriers to cancer immunotherapy","volume":"11","author":"Chung","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-024-02205-6","article-title":"Tumor metabolic regulators: Key drivers of metabolic reprogramming and the promising targets in cancer therapy","volume":"24","author":"Huang","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Jiang, J., Yan, Y., Yang, C., and Cai, H. (2025). Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic Strategies. Biomedicines, 13.","DOI":"10.3390\/biomedicines13040950"},{"key":"ref_60","first-page":"548","article-title":"Shortened Coagulation Profile in Pregnancy\u2014Comparative Analysis in Different Trimesters\u2014Retrospective Study from A Tertiary Care Centre","volume":"3","author":"Singh","year":"2016","journal-title":"Eur. J. Pharm. Med. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.3390\/cancers3043856","article-title":"Cytokines in cancer immunotherapy","volume":"3","author":"Lee","year":"2011","journal-title":"Cancers"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Atallah-Yunes, S.A., and Robertson, M.J. (2022). Cytokine based immunotherapy for cancer and lymphoma: Biology, challenges and future perspectives. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.872010"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"154732","DOI":"10.1016\/j.prp.2023.154732","article-title":"Cancer immunotherapy focusing on the role of interleukins: A comprehensive and updated study","volume":"249","author":"Samadi","year":"2023","journal-title":"Pathol.-Res. Pract."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Nguyen, K.G., Vrabel, M.R., Mantooth, S.M., Hopkins, J.J., Wagner, E.S., Gabaldon, T.A., and Zaharoff, D.A. (2020). Localized interleukin-12 for cancer immunotherapy. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.575597"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Cai, M., Huang, X., Huang, X., Ju, D., Zhu, Y.Z., and Ye, L. (2023). Research progress of interleukin-15 in cancer immunotherapy. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1184703"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.apsb.2023.12.010","article-title":"Small-molecule agents for cancer immunotherapy","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.drudis.2015.10.021","article-title":"IFN-lambda therapy: Current status and future perspectives","volume":"21","author":"Lasfar","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cbpa.2021.01.007","article-title":"Cytokine engineering for targeted cancer immunotherapy","volume":"62","author":"Bonati","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1186\/s12951-025-03613-6","article-title":"Hydrogels as advanced drug delivery platforms for cancer immunotherapy: Promising innovations and future outlook","volume":"23","author":"Mohammadzadeh","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves, A., Machado, R., Gomes, A.C., and da Costa, A. (2020). Nanotechnology solutions for controlled cytokine delivery: An applied perspective. Appl. Sci., 10.","DOI":"10.3390\/app10207098"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Fu, Y., Tang, R., and Zhao, X. (2023). Engineering cytokines for cancer immunotherapy: A systematic review. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1218082"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/ITT.S306150","article-title":"NHS-IL12, a tumor-targeting immunocytokine","volume":"10","author":"Greiner","year":"2021","journal-title":"ImmunoTargets Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e1581528","DOI":"10.1080\/2162402X.2019.1596006","article-title":"Oncolytic viruses: How \u201clytic\u201d must they be for therapeutic efficacy?","volume":"8","author":"Davola","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e004167","DOI":"10.1136\/jitc-2021-004167","article-title":"Remodeling the tumor microenvironment by oncolytic viruses: Beyond oncolysis of tumor cells for cancer treatment","volume":"10","author":"Wang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e1115641","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/oncolo\/oyad041","article-title":"Regulatory issues: PMDA\u2014Review of sakigake designation products: Oncolytic virus therapy with delytact injection (Teserpaturev) for Malignant glioma","volume":"28","author":"Maruyama","year":"2023","journal-title":"Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Gupta, A., Chavan, S.R., Gadepalli, R., and Pareek, P. (2025). Oncolytic viruses in head and neck cancers: Clinical applications and therapeutic potential. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1641267"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: A phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1003204","DOI":"10.37349\/ei.2025.1003204","article-title":"The dual promise of oncolytic viruses: Selective targeting and therapeutic enhancement in cancer treatment","volume":"5","author":"Aljabali","year":"2025","journal-title":"Explor. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Yin, Z., and Wang, Z. (2024). Strategies for engineering oncolytic viruses to enhance cancer immunotherapy. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1450203"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: Historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1623679","DOI":"10.1155\/2017\/1623679","article-title":"Clinical applications of immunotherapy combination methods and new opportunities for the future","volume":"2017","author":"Esin","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"104135","DOI":"10.1016\/j.critrevonc.2023.104135","article-title":"Immunotherapy-related biomarkers: Confirmations and uncertainties","volume":"192","author":"Catalano","year":"2023","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Knight, A., Karapetyan, L., and Kirkwood, J.M. (2023). Immunotherapy in melanoma: Recent advances and future directions. Cancers, 15.","DOI":"10.3390\/cancers15041106"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Mamdani, H., Matosevic, S., Khalid, A.B., Durm, G., and Jalal, S.I. (2022). Immunotherapy in lung cancer: Current landscape and future directions. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.823618"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","article-title":"Immunotherapy in hematologic malignancies: Achievements, challenges and future prospects","volume":"8","author":"Tang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1158\/1078-0432.CCR-21-2372","article-title":"Facts and hopes for immunotherapy in renal cell carcinoma","volume":"28","author":"Yao","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"109821","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: Pros, cons and beyond","volume":"124","author":"Tan","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Garg, P., Pareek, S., Kulkarni, P., Horne, D., Salgia, R., and Singhal, S.S. (2024). Next-generation immunotherapy: Advancing clinical applications in cancer treatment. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216537"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8481761","DOI":"10.1155\/2024\/8481761","article-title":"Tumour immunotherapy and applications of immunological products: A review of literature","volume":"2024","author":"Oli","year":"2024","journal-title":"J. Immunol. Res."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Kciuk, M., Yahya, E.B., Mohamed, M.M.I., Rashid, S., Iqbal, M.O., Kontek, R., Abdulsamad, M.A., and Allaq, A.A. (2023). Recent advances in molecular mechanisms of cancer immunotherapy. Cancers, 15.","DOI":"10.3390\/cancers15102721"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Vatsavai, N., Kaur Bhinder, S., Shaik, R., Mahira, S., Kapoor, S., Ali, M.S., Verma, D., Singh, J., Badavenkatappa Gari, S., and Upadhyay, P. (2025). Advances and challenges in cancer immunotherapy: Mechanisms, clinical applications, and future directions. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1602529"},{"key":"ref_100","first-page":"e30856","article-title":"Limitations of immunotherapy in cancer","volume":"14","author":"Gupta","year":"2022","journal-title":"Cureus"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e009063","DOI":"10.1136\/jitc-2024-009063","article-title":"Challenges and opportunities in cancer immunotherapy: A Society for Immunotherapy of Cancer (SITC) strategic vision","volume":"12","author":"Emens","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Said, S.S., and Ibrahim, W.N. (2023). Cancer resistance to immunotherapy: Comprehensive insights with future perspectives. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041143"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"El-Sayes, N., Vito, A., and Mossman, K. (2021). Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13040806"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40364-020-00209-0","article-title":"Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors","volume":"8","author":"Bai","year":"2020","journal-title":"Biomark. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13578-023-01073-9","article-title":"Overcoming acquired resistance to cancer immune checkpoint therapy: Potential strategies based on molecular mechanisms","volume":"13","author":"Wang","year":"2023","journal-title":"Cell Biosci."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Hoeben, A., Joosten, E.A.J., and van den Beuken-van Everdingen, M.H.J. (2021). Personalized medicine: Recent progress in cancer therapy. Cancers, 13.","DOI":"10.3390\/cancers13020242"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Yang, Z., Ha, B., Wu, Q., Ren, F., Yin, Z., and Zhang, H. (2025). Expanding the horizon of CAR T cell therapy: From cancer treatment to autoimmune diseases and beyond. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1544532"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Olawade, D.B., David-Olawade, A.C., Adereni, T., Egbon, E., Teke, J., and Boussios, S. (2025). Integrating AI into cancer immunotherapy\u2014A narrative review of current applications and future directions. Diseases, 13.","DOI":"10.3390\/diseases13010024"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2031699","DOI":"10.1080\/21645515.2022.2031699","article-title":"Future prospects for cancer immunotherapy-Strategies for ineffective cancers","volume":"18","author":"Wada","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","article-title":"Blinatumomab: A bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia","volume":"8","author":"Wu","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40164-024-00485-8","article-title":"Dual-targeted CAR T-cell immunotherapies for hematological malignancies: Latest updates from the 2023 ASH annual meeting","volume":"13","author":"Yang","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7216\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:08:23Z","timestamp":1786608503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":117,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27167216"],"URL":"https:\/\/doi.org\/10.3390\/ijms27167216","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}